Skip to main content
Aaron Rapoport, MD, Hematology, Baltimore, MD, University of Maryland Baltimore Washington Medical Center

AaronPaulRapoportMD

Hematology Baltimore, MD

Professor of Medicine, University MD School of Medicine

Dr. Rapoport is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rapoport's full profile

Already have an account?

Education & Training

  • University of Rochester
    University of RochesterFellowship, Hematology and Medical Oncology, 1989 - 1993
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1986 - 1989
  • Harvard Medical School
    Harvard Medical SchoolClass of 1986

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1993 - Present
  • MD State Medical License
    MD State Medical License 1997 - 2025
  • NY State Medical License
    NY State Medical License 1987 - 1998
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
  • America's Top Doctors Castle Connolly, 2012-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...  
    Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Lectures

  • Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Maryland Governor's Cancer in Remission; Treatment Continues
    Maryland Governor's Cancer in Remission; Treatment ContinuesNovember 17th, 2015
  • Immunotherapy Is the Future of Cancer Research: 70% of Multiple Myeloma Patients Find Recovery with New Treatment
    Immunotherapy Is the Future of Cancer Research: 70% of Multiple Myeloma Patients Find Recovery with New TreatmentJuly 20th, 2015
  • Gene Therapy Could Treat Cancer, Study Finds
    Gene Therapy Could Treat Cancer, Study FindsMarch 22nd, 2013

Grant Support

  • Immunotherapy After ASCT For MM Using Htert Vaccination + Vaccine-Primed T CellsNational Cancer Institute2007–2009
  • Immune Responses To T-Cell Expansion + PCV ImmunizationNational Cancer Institute2004–2005

Professional Memberships

Hospital Affiliations